Olmesartan/Amlodipine/Hctz Krka (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipine/Hctz combines three agents that act on the renin‑angiotensin system and vascular smooth‑muscle tone to lower blood pressure.

• Hypertension: provides combined blockade of angiotensin II receptors, calcium‑channel mediated vasodilation, and diuresis to achieve target blood‑pressure control.
• Resistant hypertension: adds a thiazide‑type diuretic to an ARB/CCB regimen when monotherapy or dual therapy is insufficient.
• Hypertension with edema: amlodipine‑induced peripheral edema is mitigated by the diuretic component, improving tolerability.

• Olmesartan medoxomil selectively blocks the binding of angiotensin II to AT1 receptors, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. Hydrochlorothiazide reduces sodium and water reabsorption in the distal convoluted tubule, decreasing plasma volume. The three mechanisms act synergistically to lower systemic vascular resistance and cardiac output, resulting in sustained blood‑pressure reduction.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Peripheral edema
• Flushing
• Fatigue
• Increased urination

Serious or Rare Side Effects

• Severe hypotension
• Electrolyte disturbances (e.g., low potassium, sodium)
• Acute kidney injury
• Angio‑edema
• Liver enzyme elevation
• Blood cell abnormalities (e.g., leukopenia, thrombocytopenia)

Before initiating therapy, clinicians should assess individual risk factors and monitor relevant parameters.

• Renal function: evaluate baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: check potassium and sodium levels, especially with diuretic use.
• Pregnancy: contraindicated in the second and third trimesters; avoid unless clearly needed.
• Concomitant drugs: review for potential additive blood‑pressure lowering effects.
• Elderly patients: start at lower dose and monitor for orthostatic symptoms.
• Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Olmesartan/Amlodipine/Hctz may interact with several drug classes; careful review is essential.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitor, another ARB): risk of hyperkalaemia and renal impairment.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine levels, raising hypotension risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Lithium: can increase lithium concentrations, risking toxicity.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.
• Alcohol: additive vasodilatory effect may increase dizziness.
• Digoxin: monitor levels as electrolyte shifts can affect cardiac conduction.